Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01, R21)

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

This FOA runs in parallel with another FOA of identical scientific scope, PA-18-014, which utilizes the Exploratory/Developmental Grant (R21) mechanism.


  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • R21 Due Dates: Feb. 16, Jun. 16, Oct. 16

PA-18-004 Expiration Date January 8, 2020




Medical - Basic Science
Medical - Clinical Science

External Deadline

October 5, 2019